Convergence Investment Partners’s Corcept Therapeutics CORT Stock Holding History

Convergence Investment Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,982	Closed	-$357K	–	250
2023 Q4	$357K	Buy	+10,982	New	+$302K	0.19%	116
2018 Q3	–	Sell	-74,357	Closed	-$1.17M	–	321
2018 Q2	$1.17M	Sell	74,357 -36,504	-33%	-$635K	0.16%	167
2018 Q1	$1.82M	Buy	110,861 +21,740	+24%	+$403K	0.24%	146
2017 Q4	$1.61M	Sell	89,121 -30,481	-25%	-$552K	0.22%	169
2017 Q3	$2.31M	Buy	119,602 +8,371	+8%	+$125K	0.33%	116
2017 Q2	$1.31M	Sell	111,231 -27,569	-20%	-$300K	0.19%	203
2017 Q1	$1.52M	Buy	138,800 +31,760	+30%	+$279K	0.21%	182
2016 Q4	$777K	Buy	+107,040	New	+$839K	0.11%	272

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Convergence Investment Partners's CORT Position: Q1 2024 in Review

Convergence Investment Partners sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 10,982 shares — an estimated $357K sold.

Convergence Investment Partners first reported a position in CORT in Q4 2016 and held it in 8 quarters. The position peaked at $2.31M in Q3 2017. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

Convergence Investment Partners reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
Convergence Investment Partners sold 10,982 Corcept Therapeutics shares in Q1 2024, an estimated $357K.
Convergence Investment Partners first reported a position in Corcept Therapeutics in Q4 2016 and held it in 8 quarters.
Convergence Investment Partners's Corcept Therapeutics position peaked at $2.31M in Q3 2017.
287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Convergence Investment Partners's 13F filing for Q1 2024, filed 3 May 2024.